JP2008308430A5 - - Google Patents

Download PDF

Info

Publication number
JP2008308430A5
JP2008308430A5 JP2007156997A JP2007156997A JP2008308430A5 JP 2008308430 A5 JP2008308430 A5 JP 2008308430A5 JP 2007156997 A JP2007156997 A JP 2007156997A JP 2007156997 A JP2007156997 A JP 2007156997A JP 2008308430 A5 JP2008308430 A5 JP 2008308430A5
Authority
JP
Japan
Prior art keywords
hyaluronic acid
acid
vivo
glucuronic acid
addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007156997A
Other languages
Japanese (ja)
Other versions
JP5123574B2 (en
JP2008308430A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2007156997A priority Critical patent/JP5123574B2/en
Priority claimed from JP2007156997A external-priority patent/JP5123574B2/en
Publication of JP2008308430A publication Critical patent/JP2008308430A/en
Publication of JP2008308430A5 publication Critical patent/JP2008308430A5/ja
Application granted granted Critical
Publication of JP5123574B2 publication Critical patent/JP5123574B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

ヒアルロン酸はN−アセチルグルコサミンとグルクロン酸の二糖単位が連結した構造をしており、皮膚、関節液及び眼の硝子体など生体に広く分布し、例えば皮膚においてはハリ及びその弾力性の維持等に、また関節液においては潤滑性の保持等に重要な役割を果たしている。また、ヒアルロン酸は保水性に極めて優れているため化粧品等にも使用され、また、関節炎のための医薬品等としても使用されている。また、健康食品などとしても摂取されている。しかしながらヒアルロン酸は皮膚などから吸収されず、また、経口摂取してもそのままは吸収され難い。また、生体内では、分子量が100万以上の高分子量であると言われている。
そして、ヒアルロン酸の生体内での合成は一定の年齢を過ぎると年齢とともに減少することが知られている。そのため、ヒアルロン酸の生体内での合成を促進することは皮膚の老化防止や関節等の機能維持に非常に重要と考えられ、そのような物質の探索が種々なされている。例えば、生体組織または培養細胞でヒアルロン酸の合成を促進する物質の例としては、N−アセチルグルコサミン(特開2001−2551)やN−アセチルグルコサミン誘導体(特開2004−51579)が、また、海藻の抽出物(特開平10−182402など)が知られている。
一方、ガラクチュロン酸はペクチンの主要構成成分であり、食品添加物等としても使用されているが、ヒアルロン酸生成増強作用は全く知られていない。
また、グルクロン酸は生体内においてグルクロン酸抱合等により、解毒作用を有することが知られており、グルクロン酸またはその塩は医薬品などとして使用されている。また、グルクロン酸の前駆体であるグルクロノラクトンは健康食等として経口摂取されている。しかしながら、グルクロン酸およびその塩またはグルクロノラクトンがヒアルロン酸の生成を促進する作用は知られていない。
特開2001−2551 特開2004−51579 特開平10−182402
Hyaluronic acid has a structure in which disaccharide units of N-acetylglucosamine and glucuronic acid are linked, and is widely distributed in the living body such as skin, joint fluid, and vitreous body of the eye. In addition, the synovial fluid plays an important role in maintaining lubricity. In addition, hyaluronic acid is extremely excellent in water retention and is used in cosmetics and the like, and is also used as a pharmaceutical for arthritis. It is also consumed as a health food. However, hyaluronic acid is not absorbed from the skin or the like and is hardly absorbed as it is even if taken orally. In vivo, it is said to have a high molecular weight of 1 million or more.
And, it is known that the synthesis of hyaluronic acid in vivo decreases with age after a certain age. Therefore, it is considered very important to promote the synthesis of hyaluronic acid in vivo in order to prevent skin aging and maintain the functions of joints and the like, and various searches for such substances have been made. For example, N-acetylglucosamine (Japanese Patent Laid-Open No. 2001-2551) and N-acetylglucosamine derivatives (Japanese Patent Laid-Open No. 2004-51579) are examples of substances that promote the synthesis of hyaluronic acid in living tissue or cultured cells. Extracts (such as JP-A-10-182402) are known.
On the other hand, galacturonic acid is a main component of pectin and is used as a food additive and the like, but hyaluronic acid production enhancing action is not known at all.
In addition, glucuronic acid is known to have a detoxifying action by glucuronic acid conjugation or the like in vivo, and glucuronic acid or a salt thereof is used as a medicine or the like. In addition, glucuronolactone, a precursor of glucuronic acid, is taken orally as a health food and the like. However, it is not known that glucuronic acid and a salt thereof or glucuronolactone promotes the production of hyaluronic acid .
JP2001-2551 JP 2004-51579 A JP-A-10-182402

JP2007156997A 2007-06-14 2007-06-14 Hyaluronic acid production enhancer Active JP5123574B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007156997A JP5123574B2 (en) 2007-06-14 2007-06-14 Hyaluronic acid production enhancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007156997A JP5123574B2 (en) 2007-06-14 2007-06-14 Hyaluronic acid production enhancer

Publications (3)

Publication Number Publication Date
JP2008308430A JP2008308430A (en) 2008-12-25
JP2008308430A5 true JP2008308430A5 (en) 2010-05-13
JP5123574B2 JP5123574B2 (en) 2013-01-23

Family

ID=40236355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007156997A Active JP5123574B2 (en) 2007-06-14 2007-06-14 Hyaluronic acid production enhancer

Country Status (1)

Country Link
JP (1) JP5123574B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5734578B2 (en) * 2009-09-03 2015-06-17 ナガセケムテックス株式会社 Hyaluronic acid extender
JP5715434B2 (en) * 2011-02-15 2015-05-07 日本水産株式会社 Hyaluronic acid production enhancer
JP7178127B1 (en) 2021-07-01 2022-11-25 石福金属興業株式会社 METHOD FOR MANUFACTURING FUEL CELL ELECTROCATALYST

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005298493A (en) * 2004-03-19 2005-10-27 Takeda Chem Ind Ltd Medicinal composition for preventing and/or treating chapped skin
ES2255829B1 (en) * 2004-08-06 2007-08-16 Bioiberica, S.A. NEW USE OF GLUCOSAMINE SALTS.

Similar Documents

Publication Publication Date Title
NZ624749A (en) A sulfated polysaccharide compound and the preparation and use thereof
EA200802307A1 (en) BINARY MIXES OF HYALURONIC ACID AND THEIR THERAPEUTIC APPLICATION
WO2008090631A1 (en) Fucoidan-derived oligosaccharide
BR112014014147A2 (en) cohesive fine liquids for the promotion of safe swallowing in dysphagic patients
BRPI1007325A2 (en) "Low molecular weight of polysulfated derivatives of hyaluronic acid and drugs containing hyaluronic acid."
ZA200707973B (en) Low amounts of high molecular weight polymer for enhancing viscosity of aqueous/aqueous biphasic liquids
RU2015110162A (en) WATER FOOD COMPOSITION ENRICHED WITH β-GLUCAN
NZ602249A (en) Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders
MX2009004814A (en) Nutritional products comprising saccharide oligomers.
HU230385B1 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, their preparation and use and pharmaceutical compositions containing such derivatives
CY1122198T1 (en) MEDICAL PRODUCT AND THERAPY
MX2019009711A (en) Improvements in or relating to organic compounds.
EP2289522B1 (en) Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
Zheng et al. Absorption, metabolism, and functions of hyaluronic acid and its therapeutic prospects in combination with microorganisms: A review
DE60219653D1 (en) PHARMACEUTICAL COMPOSITION WITH CHITO OLIGOMERS
JP2005507891A5 (en)
JP2008308430A5 (en)
Ahsan The significance of complex polysaccharides in personal care formulations
JP2007126453A5 (en)
ES2687900T3 (en) Derivatives of N-desulphated glycosaminoglycans and their use as drugs
Santhosh et al. Preparation and properties of glucosamine and carboxymethylchitin from shrimp shell
WO2007059874A3 (en) Compositions for the treatment of osteoarthritis and to nourish the synovial fluid
JP2009096807A (en) Prophylactic or therapeutic agent for allergic disease
JP5123574B2 (en) Hyaluronic acid production enhancer
JP2004137183A (en) Oral administration medicine, health food product or nutritional medicine composition containing glucosaminoglycan or its salt